U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C12H24O2.C2H6NO3S.Na
Molecular Weight 347.446
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM TAURINE LAURATE

SMILES

[Na+].NCCS([O-])(=O)=O.CCCCCCCCCCCC(O)=O

InChI

InChIKey=HLGSTHXLGGPEDB-UHFFFAOYSA-M
InChI=1S/C12H24O2.C2H7NO3S.Na/c1-2-3-4-5-6-7-8-9-10-11-12(13)14;3-1-2-7(4,5)6;/h2-11H2,1H3,(H,13,14);1-3H2,(H,4,5,6);/q;;+1/p-1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C12H24O2
Molecular Weight 200.3178
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C2H6NO3S
Molecular Weight 124.139
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3676193 | http://www.medscape.com/viewarticle/804080 | https://www.ncbi.nlm.nih.gov/pubmed/21334852 | https://www.ncbi.nlm.nih.gov/pubmed/26208967

Taurine is a semi-essential amino acid and is not incorporated into proteins. Taurine is considered conditionally essential because it cannot be synthesized by infants younger than 4-6 weeks, and it may not be adequately synthesized in patients receiving long-term parenteral nutrition and patients with short-term hypermetabolic conditions. In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg. Taurine is a component of energy drinks, with many contain 1000 mg per serving. In medicine, taurine supplementation demonstrated efficacy in relieving symptoms of heart failure, hepatitis, hypertension and psychotic disorder. Taurine exerts many physiological functions, including membrane stabilization, osmoregulation and cytoprotective effects, antioxidant and anti-inflammatory actions as well as modulation of intracellular calcium concentration and ion channel function. In addition taurine may control muscle metabolism and gene expression, through yet unclear mechanisms. The cellular and biochemical mechanisms mediating the actions of taurine are not fully known.

CNS Activity

Originator

Tiedemann, F.|Gmelin, L.
5
Curator's Comment: Taurin was first isolated from ox bile in 1827.

Approval Year

1984
110
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
Agonist
2752
 406.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
TAURINE

Approved Use

Taking 2-3 grams of taurine by mouth one to two times daily for 6-8 weeks seems to improve heart function and symptoms in patients with moderate heart failure to severe heart failure. Some patients with severe heart failure rapidly improve from NYHA class IV to II after 4-8 weeks of treatment. Improvement seems to continue for as long as taurine treatment is continued, up to one year.
Palliative
Approved
8583
TAURINE

Approved Use

Taking 1.5-4 grams of taurine daily for up to 3 months improves liver function in people with hepatitis.
Preventing
Approved
8583
URSA Complex

Approved Use

Taurine is a component of energy drinks used for relieving of fatigue
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Phase III
665
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
86.1 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22331997/
4 g single, oral
dose: 4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
TAURINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
206.3 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22331997/
4 g single, oral
dose: 4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
TAURINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22331997/
4 g single, oral
dose: 4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
TAURINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
PubMed

PubMed

TitleDatePubMed
Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection.
2001 Apr 13
Mast cell numbers in the young rat thalamus: a search for control factors.
2001 Aug
Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels.
2001 Feb
Hamster sperm glycine receptor: evidence for its presence and involvement in the acrosome reaction.
2001 Feb
Taurine and osmoregulation: platelet taurine content, uptake, and release in type 2 diabetic patients.
2001 Jan
MR diffusion imaging and 1H spectroscopy in a child with medulloblastoma. A case report.
2001 Jan
Studies on the effects of lactate transport inhibition, pyruvate, glucose and glutamine on amino acid, lactate and glucose release from the ischemic rat cerebral cortex.
2001 Jan
Neurotoxic effect of acamprosate, n-acetyl-homotaurine, in cultured neurons.
2001 Jan-Feb
The European acamprosate trials: conclusions for research and therapy.
2001 Jan-Feb
The effect of taurine depletion by beta-alanine treatment on the susceptibility to ethanol-induced hepatic dysfunction in rats.
2001 Jan-Feb
Effect of starvation on free histidine and amino acids in white muscle of milkfish Chanos chanos.
2001 Mar
Intrathecal magnesium sulfate attenuates algogenic behavior and spinal amino acids release after kainic acid receptor activation in rats.
2001 Mar 30
High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1.
2001 May
Patents

Patents

04227014
7
05352805
5
06503949
10
06881755
5
07294185
6

Sample Use Guides

In Vivo Use Guide
Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg.
Route of Administration: Oral
In Vitro Use Guide
Agonist properties of taurine on glycine receptor of supraoptic magnocellular neurones acutely dissociated from adult rats, using whole-cell voltage clamp. Responses to 1 mM taurine were blocked by strychnine but not by gabazine and showed no additivity with glycine-induced currents, indicating selective activation of glycine receptors.
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:58:58 GMT 2025
Edited
by admin
on Mon Mar 31 20:58:58 GMT 2025
Record UNII
ZYS0US400F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DODECANOIC ACID, 2-AMINOETHANESULFONIC, SODIUM SALT
Preferred Name English
SODIUM TAURINE LAURATE
INCI  
INCI  
Official Name English
DODECANOIC ACID, COMPD. WITH 2-AMINOETHANESULFONIC ACID MONOSODIUM SALT (1:1)
Common Name English
ETHANESULFONIC ACID, 2-AMINO-, COMPD. WITH DODECANOIC ACID, SODIUM SALT (1:1:1)
Common Name English
ETHANESULFONIC ACID, 2-AMINO-, MONOSODIUM SALT, DODECANOATE
Common Name English
Code System Code Type Description
FDA UNII
ZYS0US400F
Created by admin on Mon Mar 31 20:58:58 GMT 2025 , Edited by admin on Mon Mar 31 20:58:58 GMT 2025
PRIMARY
EPA CompTox
DTXSID00172872
Created by admin on Mon Mar 31 20:58:58 GMT 2025 , Edited by admin on Mon Mar 31 20:58:58 GMT 2025
PRIMARY
RXCUI
2399553
Created by admin on Mon Mar 31 20:58:58 GMT 2025 , Edited by admin on Mon Mar 31 20:58:58 GMT 2025
PRIMARY
CAS
192750-09-7
Created by admin on Mon Mar 31 20:58:58 GMT 2025 , Edited by admin on Mon Mar 31 20:58:58 GMT 2025
PRIMARY
PUBCHEM
23668864
Created by admin on Mon Mar 31 20:58:58 GMT 2025 , Edited by admin on Mon Mar 31 20:58:58 GMT 2025
PRIMARY
Related Record Type Details
Structure of LAURIC ACID
PARENT -> SALT/SOLVATE
Structure of TAURINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of TAURINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966